ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

APLT Applied Therapeutics Inc

4.67
-0.59 (-11.22%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 672,435
Bid Price 4.70
Ask Price 5.24
News -
Day High 5.28

Low
1.18

52 Week Range

High
9.39

Day Low 4.93
Company Name Stock Ticker Symbol Market Type
Applied Therapeutics Inc APLT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.59 -11.22% 4.67 19:39:13
Open Price Low Price High Price Close Price Prev Close
5.23 4.93 5.28 5.05 5.26
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,711 672,435 $ 5.08 $ 3,415,941 - 1.18 - 9.39
Last Trade Time Type Quantity Stock Price Currency
19:08:45 1 $ 5.25 USD

Applied Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
534.73M 105.89M - 9.99M -119.76M -1.13 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Applied Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No APLT Message Board. Create One! See More Posts on APLT Message Board See More Message Board Posts

Historical APLT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.505.50994.445.101,202,4590.173.78%
1 Month4.315.50993.954.60767,1330.368.35%
3 Months6.877.393.955.05800,372-2.20-32.02%
6 Months3.059.391.854.661,507,9011.6253.11%
1 Year1.429.391.183.841,134,2383.25228.87%
3 Years23.2225.590.49953.53569,550-18.55-79.89%
5 Years9.8657.390.49957.25396,146-5.19-52.64%

Applied Therapeutics Description

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

Your Recent History

Delayed Upgrade Clock